Conditions Treated by Hyperbaric Oxygen Therapy (HBOT): From FDA-Approved to Emerging Frontiers

What if a therapy backed by decades of research could tackle life-threatening emergencies, speed up wound healing, and show promise for stubborn neurological and chronic issues? That's Hyperbaric Oxygen Therapy (HBOT) in action — delivering pure oxygen under pressure to supercharge healing where it's needed most.

As of 2025–2026, HBOT remains a cornerstone treatment with clear FDA-cleared indications (often insurance-reimbursable) and a growing body of evidence for emerging uses. The Undersea and Hyperbaric Medical Society (UHMS) guides standards, listing 14–15 approved indications based on rigorous evidence (15th Edition updates emphasize proven applications like diabetic wounds and radiation injury).

Let's break it down with the latest insights.

FDA-Cleared / UHMS-Approved Indications: Proven & Often Covered

These are the gold-standard uses, supported by strong clinical data and frequently reimbursed by insurance. The FDA and UHMS align on these core conditions (updated through 2025 guidelines):

• Air or Gas Embolism — Bubbles blocking blood flow, often from diving or medical procedures.
• Decompression Sickness ("the bends") — Rapid pressure changes in divers.
• Carbon Monoxide Poisoning — Including cases complicated by cyanide exposure.
• Gas Gangrene (Clostridial Myonecrosis) — Severe bacterial infection producing tissue gas.
• Necrotizing Soft Tissue Infections — Life-threatening flesh-eating bacteria.
• Crush Injury & Acute Traumatic Ischemias — Including compartment syndrome from severe trauma.
• Chronic Non-Healing Wounds — Especially diabetic foot ulcers and selected problem wounds.
• Delayed Radiation Injuries — Soft tissue and bony necrosis from cancer treatment.
• Compromised Skin Grafts & Flaps — Enhancing survival of transplanted tissue.
• Thermal Burns — Adjunctive for severe, large burns in specialized centers.
• Refractory Osteomyelitis — Chronic bone infections unresponsive to standard care.
• Severe Anemia — When transfusions aren't possible.
• Intracranial Abscess — Brain infections.
• Central Retinal Artery Occlusion & Idiopathic Sudden Sensorineural Hearing Loss — Emerging in UHMS lists for vascular emergencies.
• Exceptional Blood Loss Anemia (in some listings).

These indications stem from peer-reviewed research showing HBOT's ability to reverse hypoxia, fight infection, promote angiogenesis, and reduce inflammation. For example, diabetic foot ulcers see reduced amputations and faster closure with adjunctive HBOT.

Emerging & Off-Label Applications: Promising Research (2024–2026)

While not yet FDA-approved (and often off-label), these show strong potential in studies, registries, and clinical trials. A 2024 multicenter registry of 9,726 patients highlighted benefits in non-approved uses, with significant improvements in patient-reported outcomes.

• Traumatic Brain Injury (TBI) & Post-Concussion Syndrome — 2025 meta-analyses (including 250+ patients) demonstrate gains in memory (+10.13 points), attention (+7.99 points), executive function, and cognition. Double-blind trials confirm neuroplasticity benefits and symptom reduction.
• Stroke Recovery — Enhances neuroplasticity, reduces oxidative stress, and improves outcomes in chronic phases (bibliometric reviews up to 2025).
• Post-Traumatic Stress Disorder (PTSD) — 2025 studies show threshold effects for sustained symptom improvement (e.g., 35%+ reduction), better brain connectivity, and quality-of-life gains, especially in veterans with comorbid TBI.
• Post-COVID Condition (Long COVID) — Registry data (149 cases) report major Neurobehavioral Symptom Inventory improvements (from 30.6 to 14.4).
• Inflammatory Bowel Disease (IBD) — Ulcerative colitis and Crohn's show better quality of life, fistula closure in some, and reduced symptoms.
• Other Promising Areas — Calciphylaxis, frostbite, peripheral vascular wounds, fibromyalgia (pain/fatigue relief), and adjunctive roles in Lyme disease, chronic fatigue, and more. Autism and MS remain investigational with mixed but hopeful early data.

A 2025 review notes HBOT's neuromodulatory effects across neurological/psychiatric conditions, with ongoing trials exploring dosing and long-term outcomes.

International Scope: Over 100+ Indications Globally

Internationally, HBOT is recognized for far more conditions (often 100+ across countries), varying by regulatory bodies like the European Committee for Hyperbaric Medicine (ECHM). This reflects broader acceptance in places like Europe, Asia, and beyond for adjunctive uses in wounds, infections, and neurological issues. The UHMS registry and global consensus continue to expand evidence-based applications.

The Bottom Line: HBOT's Versatile Role in Healing

HBOT excels in acute, life-saving scenarios (FDA-approved) while offering exciting potential for chronic and neurological challenges (emerging evidence). Always work with a qualified provider — preferably at a UHMS-accredited facility — for personalized protocols and safety.

Dealing with one of these conditions or curious about HBOT for recovery? Share your story below — let's talk evidence-based options!

Stay empowered with the latest science. 💨🧬